Why I think the AstraZeneca share price will keep climbing

A portfolio of new drugs could mean it’s time to invest in AstraZeneca plc (LON: AZN).

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Big pharma firms have seen one major issue causing them trouble for many years now – the availability of cheap, generic versions of the drugs they researched and created as their patents run out. This week however, the release of its latest half-year figures suggests AstraZeneca (LSE: AZN) seems to be bucking this trend.

The numbers don’t lie

Thursday’s figures showed the fourth consecutive quarter of rising revenue for Astra, brought about in large part by strong sales performance for a number of its new drugs. Notably, its cancer medications Tagrisso and Imfinzi have been very strong performers, with H1 sales of $1.4bn and $633m respectively.

AstraZeneca has taken a somewhat different approach to cancer treatment compared to its major rivals. While the majority of research and money is spent on drugs aimed at the Stage 4 level of the disease, Astra has instead focused its efforts on early treatment and detection, carving a niche for itself in this competitive industry.

This has helped its numbers, with Q2 sales rising 19% to $5.7bn, while earnings per share came in at $0.73, beating expectations by more than ten cents. The company upgraded its product sales guidance for the year to “low double-digit figures” and said that in addition to its cancer treatments, it expects heart disease drug Brilinta and diabetic medicine Farxiga to reach so-called ‘blockbuster’ status, seeing annual sales in excess of $1bn each.

Buy high, sell higher!

Something I learned early in my investing career was that the old adage of buy low, sell high is easier said than done, and often works out as a losing strategy. Instead the phrase buy high, sell higher, might be better. Buying shares while they are on the up, hopefully as early as possible, can be a more consistent strategy. Looking at AstraZeneca, I think it may just be a candidate for this type of investment.

Its current share price is a solid £68, not far from its all-time highs, bringing about a dividend yield just above the 3% mark. While none of this seems to be a bargain exactly, I can’t help but think there is not likely to be a large enough dip in the price any time soon that would be worth waiting for (hopefully not famous last words). On the other hand, this upward trend could easily continue for the next year or so before coming up against any significant resistance (if even then).

The company did say that it doesn’t expect its performance in the second half of the year to be as strong as the first, but managing expectations like this usually helps avoid any nasty price shocks. Given the strength and breadth of its drugs portfolio, and notably its strong performance in China (Astra’s Chinese sales grew 44% in H1), where generic drugs are common, I think these latest figures could keep the share price climbing.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Karl has no position in any of the shares mentioned. The Motley Fool UK has recommended AstraZeneca. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Up 105% in a year! Is this rocketing FTSE bank the perfect pick for my Stocks and Shares ISA?

Harvey Jones is drawing up a shortlist of stocks to purchase inside his Stocks and Shares ISA allowance. This FTSE…

Read more »

Investing Articles

Is it madness to buy Palantir shares after Q3 earnings?

Palantir stock's surging again after the firm's Q3 earnings report. But after a 150% gain, is it too late to…

Read more »

A pastel colored growing graph with rising rocket.
Investing Articles

£6,000 in savings? Here’s how I’d aim to turn that into £1,032 a month of passive income!

A small investment in high-dividend-paying stocks with the returns used to buy more shares can generate big passive income over…

Read more »

Chalkboard representation of risk versus reward on a pair of scales
Investing Articles

As Lloyds’ share price tumbles 14%, is this an unmissable opportunity for me to buy at a bargain-basement price?

The Lloyds share price is substantially below its year high, but decent earnings prospects should drive its price and dividend…

Read more »

The flag of the United States of America flying in front of the Capitol building
Investing Articles

2 UK shares that could rise if Trump wins the Presidential election

These UK shares are among the FTSE 100's most popular stocks. And they could rise in value if Donald Trump…

Read more »

Closeup ruffled American flag representing US stocks and shares
Investing Articles

2 UK stocks that could rise if Harris wins the Presidential election

Royston Wild believes these UK stocks could receive a bump if Kalama Harris wins the Presidency, giving their share prices…

Read more »

Investing Articles

After a 96% plunge, is buying more Aston Martin shares throwing good money after bad?

Just two weeks after buying Aston Martin shares Harvey Jones found himself nursing a painful loss. Yet after recent news…

Read more »

Investing Articles

After crashing 45% in October, should I buy this FTSE 250 share for my Stocks and Shares ISA?

Roland Head explains why he’s tempted to add this risky FTSE 250 turnaround share to his Stocks and Shares ISA…

Read more »